227 related articles for article (PubMed ID: 8558219)
1. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; O'Sullivan J; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Osborne CK
J Clin Oncol; 1996 Jan; 14(1):46-51. PubMed ID: 8558219
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
3. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Jewell WR; Costanzi JJ; Altman SJ; Minton JP; O'Bryan RM; Osborne CK
J Clin Oncol; 1993 Sep; 11(9):1710-6. PubMed ID: 8355037
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
[TBL] [Abstract][Full Text] [Related]
6. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.
Budd GT; Green S; O'Bryan RM; Martino S; Abeloff MD; Rinehart JJ; Hahn R; Harris J; Tormey D; O'Sullivan J
J Clin Oncol; 1995 Apr; 13(4):831-9. PubMed ID: 7707108
[TBL] [Abstract][Full Text] [Related]
7. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Albain KS; Green S; LeBlanc M; Rivkin S; O'Sullivan J; Osborne CK
Breast Cancer Res Treat; 1992; 22(3):273-84. PubMed ID: 1391993
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy of breast cancer: Southwest Oncology Group studies.
Osborne CK; Rivkin SE; McDivitt RW; Green S; Stephens RL; Costanzi JJ; O'Bryan R
NCI Monogr; 1986; (1):71-4. PubMed ID: 3534592
[TBL] [Abstract][Full Text] [Related]
9. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Perloff M; Norton L; Korzun AH; Wood WC; Carey RW; Gottlieb A; Aust JC; Bank A; Silver RT; Saleh F; Canellos GP; Perry MC; Weiss RB; Holland JF
J Clin Oncol; 1996 May; 14(5):1589-98. PubMed ID: 8622076
[TBL] [Abstract][Full Text] [Related]
10. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
Castiglione-Gertsch M; Johnsen C; Goldhirsch A; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Hacking A; Cortes-Funes H; Forbes J
Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
Knight WA; Rivkin SE; Glucksberg H; Foulkes MA; Costanzi JJ; Stephens RL; Athens JW; O'Bryan RM
Breast Cancer Res Treat; 1983; 3 Suppl():S27-33. PubMed ID: 6367857
[TBL] [Abstract][Full Text] [Related]
12. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Mansour EG; Eudey L; Tormey DC; Shatila AH; Osborne CK; Gilchrist KW; Cooper MR; Falkson G
J Natl Cancer Inst Monogr; 1992; (11):97-104. PubMed ID: 1627437
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
Rivkin SE; Knight WA; McDivitt R; Cruz T; Foulkes M; Osborne CK; Fabian CJ; Costanzi JJ
J Steroid Biochem; 1985 Dec; 23(6B):1151-4. PubMed ID: 3912621
[TBL] [Abstract][Full Text] [Related]
19. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
Clahsen PC; van de Velde CJ; Julien JP; Floiras JL; Delozier T; Mignolet FY; Sahmoud TM
J Clin Oncol; 1996 Mar; 14(3):745-53. PubMed ID: 8622020
[TBL] [Abstract][Full Text] [Related]
20. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
